DOCSLIB.ORG

Pharmacodynamics of Ceftibuten: an Assessment of an Oral Cephalosporin Against Enterobacterales in a Neutropenic Murine Thigh Model

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacodynamics of Ceftibuten: an Assessment of an Oral Cephalosporin Against Enterobacterales in a Neutropenic Murine Thigh Model antibiotics Article Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model Maxwell J. Lasko 1, Tomefa E. Asempa 1 and David P. Nicolau 1,2,* 1 Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; [email protected] (M.J.L.); [email protected] (T.E.A.) 2 Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102, USA * Correspondence: [email protected]; Tel.: +1-860-972-3941; Fax: +1-860-545-3992 Abstract: Efforts to develop and pair novel oral β-lactamase inhibitors with existing β-lactam agents to treat extended spectrum β-lactamase (ESBL) and carbapenemase-producing Enterobacterales are gaining ground. Ceftibuten is an oral third-generation cephalosporin capable of achieving high urine concentrations; however, there are no robust data describing its pharmacodynamic profile. This study characterizes ceftibuten pharmacokinetics and pharmacodynamics in a neutropenic murine thigh in- fection model. Enterobacterales isolates expressing no known clinically-relevant enzymatic resistance (n = 7) or harboring an ESBL (n = 2) were evaluated. The ceftibuten minimum inhibitory concentra- tions (MICs) were 0.03–4 mg/L. Nine ceftibuten regimens, including a human-simulated regimen (HSR) equivalent to clinical ceftibuten doses of 300 mg taken orally every 8 h, were utilized to achieve various f T > MICs. A sigmoidal Emax model was fitted to f T > MIC vs. change in log10 CFU/thigh to determine the requirements for net stasis and 1-log10 CFU/thigh bacterial burden reduction. Citation: Lasko, M.J.; Asempa, T.E.; The growth of the 0 h and 24 h control groups was 5.97 ± 0.37 and 8.51 ± 0.84 log CFU/thigh, Nicolau, D.P. Pharmacodynamics of 10 respectively. Ceftibuten HSR resulted in a -0.49 to -1.43 log CFU/thigh bacterial burden reduction Ceftibuten: An Assessment of an Oral 10 Cephalosporin against at 24 h across the isolates. Stasis and 1-log10 CFU/thigh reduction were achieved with a f T > MIC of Enterobacterales in a Neutropenic 39% and 67%, respectively. The f T > MIC targets identified can be used to guide ceftibuten dosage Murine Thigh Model. Antibiotics 2021, selection to optimize the likelihood of clinical efficacy. 10, 201. https://doi.org/10.3390/ antibiotics10020201 Keywords: pharmacokinetics; pharmacodynamics; Gram-negative; beta-lactamase Academic Editors: Nicholas Dixon and Anthony William Coleman Received: 6 January 2021 1. Introduction Accepted: 16 February 2021 Gram-negative Enterobacterales that harbor extended spectrum β-lactamases (ESBLs) Published: 19 February 2021 and carbapenemases continue to be a burden on healthcare [1–3]. ESBLs, in particular, are frequent causes of infection in both hospitalized and community-dwelling patients [1,3]. Publisher’s Note: MDPI stays neutral Few oral therapeutic options exist, resulting in the use of intravenous broad-spectrum with regard to jurisdictional claims in antibiotics (i.e., carbapenems) with the potential for further resistance development [4,5]. published maps and institutional affil- iations. Moreover, infections caused by ESBL-harboring Enterobacterales are associated with an approximately two-fold increase in the cost of hospitalization and the length of stay compared with β-lactamase naïve infections [6]. The clear need for carbapenem-sparing antibiotics that can effectively treat ESBL- harboring Enterobacterales has spurred numerous oral drug development efforts over the Copyright: © 2021 by the authors. past several years [7]. Additionally, the availability of an effective oral agent targeting these Licensee MDPI, Basel, Switzerland. challenging organisms would provide a significant therapeutic breakthrough for patients This article is an open access article treated outside the institutional setting. Thus, repurposing older and infrequently utilized distributed under the terms and oral β-lactam agents, such as ceftibuten, cefixime, and cefpodoxime, to be paired with conditions of the Creative Commons β Attribution (CC BY) license (https:// investigational -lactamase inhibitors (BLIs), has become an attractive option. creativecommons.org/licenses/by/ Ceftibuten has been explored as a β-lactam (BL) backbone because of its excellent 4.0/). bioavailability (75–90%) and high fractional excretion in urine [8,9]. In addition, ceftibuten Antibiotics 2021, 10, 201. https://doi.org/10.3390/antibiotics10020201 https://www.mdpi.com/journal/antibiotics Antibiotics 2021, 10, x FOR PEER REVIEW 2 of 10 utilized oral β-lactam agents, such as ceftibuten, cefixime, and cefpodoxime, to be paired with investigational β-lactamase inhibitors (BLIs), has become an attractive option. Ceftibuten has been explored as a β-lactam (BL) backbone because of its excellent bioavailability (75–90%) and high fractional excretion in urine [8,9]. In addition, ceftibuten Antibiotics 2021, 10, 201 demonstrates improved in vitro stability against ESBLs compared with other2 of oral 10 third- generation cephalosporins [8,9]. Ceftibuten’s pharmacodynamic driver is free drug time above MIC (fT > MIC). The fT > MIC requirements that best correlate with cephalosporin demonstratesefficacy vary improvedfrom 40–50%,in vitro as reportedstability against by the ESBLsEuropean compared Committee with other on Antimicrobial oral third- Sus- generationceptibility cephalosporinsTesting (EUCAST) [8,9]. scientific Ceftibuten’s committee pharmacodynamic [10], to as driverhigh as is 50–70% free drug [11,12]. time How- aboveever, a MIC formal (f T > ceftibuten MIC). The fpharmacodynamicT > MIC requirements assessment that best correlate against with clinically-relevant cephalosporin Enter- efficacyobacterales vary has from never 40–50%, been as performed. reported by Previously the European published Committee studies on Antimicrobial have focused on the Susceptibilityactivity of ceftibuten Testing (EUCAST) in combination scientific with committee BLIs, with [10 ],a tofocus as high on understanding as 50–70% [11,12 BLI]. expo- However, a formal ceftibuten pharmacodynamic assessment against clinically-relevant sure requirements for efficacy [13,14]. Thus, ceftibuten-specific pharmacodynamic profil- Enterobacterales has never been performed. Previously published studies have focused oning the is activityneeded of in ceftibuten order to inbetter combination understand with BLIs,the scope with a and focus potential on understanding utility of BLI a range of exposureexposures requirements prior to their for combination efficacy [13,14 with]. Thus, a novel ceftibuten-specific BLI. Herein, pharmacodynamicwe describe a pharmaco- profilingdynamic isassessment needed in of order ceftibuten to better in understand a neutropenic the murine scope and thigh potential infection utility model. of a range of exposures prior to their combination with a novel BLI. Herein, we describe a pharmacodynamic2. Results assessment of ceftibuten in a neutropenic murine thigh infection model. 2.2.1. Results Murine Pharmacokinetic Studies 2.1. MurineCeftibuten Pharmacokinetic single doses Studies were well characterized using a uniform one-compartment modelCeftibuten with first-order single doses absorption were well and characterized elimination using (Figure a uniform 1). Furthermore, one-compartment the pharma- modelcokinetics with of first-order ceftibuten absorption were relative and eliminationly linear (area (Figure under1). Furthermore, the curve (AUC) the pharma- R2 0.98) over cokineticsthe single of doses ceftibuten administered were relatively using linear non-compartmental (area under the curve analysis (AUC) R(Table2 0.98) 1). over The the elimina- singletion half-life doses administered ranged from using 1.0 to non-compartmental 1.8 h. The mean (± analysis standard (Table deviation1). The elimination (SD)) pharmacoki- half-life ranged from 1.0 to 1.8 h. The mean (± standard deviation (SD)) pharmacokinetic netic parameters, namely, volume of distribution (Vd), 0.342 ± 0.09 (L/kg); absorption con- parameters, namely, volume of distribution (Vd), 0.342 ± 0.09 (L/kg); absorption constant stant (Ka), 5.45 ± 2.46 (1/h); and elimination constant (Ke), 0.60 ± 0.17 (1/h), were used to (Ka), 5.45 ± 2.46 (1/h); and elimination constant (Ke), 0.60 ± 0.17 (1/h), were used to simulate ceftibutenceftibuten regimens regimens and and obtain obtain concentration–time concentration–time profiles. profiles. Comparisons Comparisons of the of the %fT %> fMICT > MIC values values achieved achieved with with ceftibuten ceftibuten at atMICs MICs ranging ranging between between 0.030.03 andand 4 4 mg/L, mg/L, as as well as wellthe area as the under area underthe concentration–time the concentration–time curve curve from from 0 to 024 to h 24 for h forthe thefree, free, unbound unbound fraction of fraction of the drug (f AUC ), in mice receiving the selected regimens are presented the drug (fAUC0–24), in mice0–24 receiving the selected regimens are presented in Table 2. in Table2. Figure 1.1.Ceftibuten Ceftibuten free free plasma plasma concentration–time concentration–time profiles profiles in a neutropenic in a neutropenic mouse thigh mouse infection thigh infec- modeltion model following following the administration the administration of single of subcutaneous single subcutaneous doses (0.5–45 doses mg/kg). (0.5–45 mg/kg). Antibiotics 2021, 10, 201 3 of 10 Table 1. Comparison of single dose ceftibuten regimens in mice using non-compartmental analysis. 2 Single Dose Regimen λ1/2 (h) fCmax fAUC0–8 R
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Antibiotic Review
    8/28/19 Disclosure 2 E. Monee’ Carter-Griffin DNP, MA, RN, ACNP-BC Antibiotic has no financial relationships with commercial Review interests to disclose. Any unlaBeled and/or E. Monee’ Carter-Griffin, DNP, MA, RN, ACNP-BC unapproved uses of drugs or products will Be Associate Chair for Advanced Practice Nursing disclosed. University of Texas at Arlington, College of Nursing & Health Innovation Dallas Pulmonary & Critical Care, PA • Identify the general characteristics of • SusceptiBility à determine which antibiotics. antibiotics a bacteria is sensitive to • Discuss the mechanism of action, • à pharmacokinetics, and spectrum of activity MIC lowest concentration of drug that inhiBits growth of the Bacteria for the most common antiBiotic drug classes. Antibiotic Objectives • Identify commonly prescriBed antiBiotics • Trough à lowest concentration of within the drug classes including dosage Lingo drug in bloodstream range and indication for prescribing. – Collect prior to administration of • Identify special considerations for specific drug antibiotics and/or drug classes. • Peak à highest concentration of • Practice appropriate prescriBing for common drug in bloodstream bacterial infections. • Review Basic antiBiotic stewardship 3 4 principles. • Penicillins • Bactericidal or bacteriostatic • Cephalosporins • Narrow or Broad spectrum • Carbapenems General • Can elicit allergic responses Antibiotic • MonoBactam Characteristics • Affect normal Body flora Drug Classes • Macrolides • Fluoroquinolones • Sulfonamides • Tetracyclines 5 6 1 8/28/19 • Penicillins – Natural penicillins 8 – Aminopenicillins Penicillins Penicillins – Anti-staphylococcal penicillins • Mechanism of action àbactericidal à – Anti-pseudomonal penicillins interrupts cell wall synthesis 7 • Pharmacokinetics • Spectrum of Activity – Gram positive organisms Natural – Penicillin G à mostly given IM, But Natural • Streptococcus species (e.g. S. Penicillins one variation can Be given IV Penicillins pyogenes) • Poorly aBsorBed via PO • Some enterococcus species (e.g.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Ceftibuten (hydrate) Item No. 25334 NH2 S CAS Registry No.: 118081-34-8 N Formal Name: (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-4-carboxy- 1-oxo-2-buten-1-yl]amino]-8-oxo-5-thia-1- O azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, dihydrate • 2H2O Synonym: SCH 39720 H N S MF: C15H14N4O6S2 • 2H2O HO FW: 446.5 H O Purity: ≥98% O N UV/Vis.: λmax: 218, 262 nm Supplied as: A crystalline solid -20°C O Storage: OH Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Ceftibuten (hydrate) is supplied as a crystalline solid. A stock solution may be made by dissolving the ceftibuten (hydrate) in the solvent of choice. Ceftibuten (hydrate) is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of ceftibuten (hydrate) in these solvents is approximately 5 and 2 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of ceftibuten (hydrate) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of ceftibuten (hydrate) in PBS, pH 7.2, is approximately 0.1 mg/ml. We do not recommend storing the aqueous solution for more than one day.
    [Show full text]
  • Cephalosporins Can Be Prescribed Safely for Penicillin-Allergic Patients ▲
    JFP_0206_AE_Pichichero.Final 1/23/06 1:26 PM Page 106 APPLIED EVIDENCE New research findings that are changing clinical practice Michael E. Pichichero, MD University of Rochester Cephalosporins can be Medical Center, Rochester, NY prescribed safely for penicillin-allergic patients Practice recommendations an allergic reaction to cephalosporins, ■ The widely quoted cross-allergy risk compared with the incidence of a primary of 10% between penicillin and (and unrelated) cephalosporin allergy. cephalosporins is a myth (A). Most people produce IgG and IgM antibodies in response to exposure to ■ Cephalothin, cephalexin, cefadroxil, penicillin1 that may cross-react with and cefazolin confer an increased risk cephalosporin antigens.2 The presence of of allergic reaction among patients these antibodies does not predict allergic, with penicillin allergy (B). IgE cross-sensitivity to a cephalosporin. ■ Cefprozil, cefuroxime, cefpodoxime, Even penicillin skin testing is generally not ceftazidime, and ceftriaxone do not predictive of cephalosporin allergy.3 increase risk of an allergic reaction (B). Reliably predicting cross-reactivity ndoubtedly you have patients who A comprehensive review of the evidence say they are allergic to penicillin shows that the attributable risk of a cross- U but have difficulty recalling details reactive allergic reaction varies and is of the reactions they experienced. To be strongest when the chemical side chain of safe, we often label these patients as peni- the specific cephalosporin is similar to that cillin-allergic without further questioning of penicillin or amoxicillin. and withhold not only penicillins but Administration of cephalothin, cepha- cephalosporins due to concerns about lexin, cefadroxil, and cefazolin in penicillin- potential cross-reactivity and resultant IgE- allergic patients is associated with a mediated, type I reactions.
    [Show full text]
  • Assessment of the Palatability of Antibiotic Oral Suspensions: a Literature Review S
    Assessment of the palatability of antibiotic oral suspensions: a literature review S. ROBERT1, Y-E NISSE1, B. DEMORE1,2 4CPS-205 1 Pharmacie, CHRU Nancy, Nancy, France ; 2 APEMAC, Université de Lorraine, Nancy, France Corresponding author: [email protected] Background Non adherence to a full course of antibiotic occurs in approximately one-quarter of paediatric patients. The child’s refusal to take the drug is the second most common reason for non-adherence. Palatability is the third most important antibiotic feature for parents after effectiveness and safety Objective Review the literature for assessments of the palatability of antibiotic oral suspensions to inform physicians in their daily practice and consequently improve adherence Materials & methods Research date Inclusion criteria Results reporting august 2019 study reporting an assessment of palatability lowest score = poor palatability of one or more antibiotic suspensions highest score = excellent palatability Database with any assessment scale pubMed Database Data extracted all results are expressed on a 10-point scale for comparison purposes Population study characteristics population demographics separate averages were calculated for adults and/or children palatability assessments adults and children Results Palatability of antibiotic oral suspensions in children and adults Study characteristics Adults Children 9 9 studies identified 8 8 only blind studies 7 7 9/10 with healthy volunteers 6 6 5 5 4 4 3 3 2 adults only children only 2 1 1 SU RIF CLI FA LEX SXT CLR CEC ERY CTB CPR LZD CPD LOR DCX CFM LEX OXA CLR CXM ERY AMP CPR AMX AZM AMC CPD DCX CDR CFM CXM AMX AZM AMC PEN V PEN VK ERY/SU ERY/SU For a given antibiotic, each bar represents a study.
    [Show full text]
  • A Thesis Entitled an Oral Dosage Form of Ceftriaxone Sodium Using Enteric
    A Thesis entitled An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy Option _________________________________________ Jerry Nesamony, Ph.D., Committee Chair _________________________________________ Sai Hanuman Sagar Boddu, Ph.D, Committee Member _________________________________________ Youssef Sari, Ph.D., Committee Member _________________________________________ Patricia R. Komuniecki, PhD, Dean College of Graduate Studies The University of Toledo May 2015 Copyright 2015, Darshan Narendra Lalwani This document is copyrighted material. Under copyright law, no parts of this document may be reproduced without the expressed permission of the author. An Abstract of An oral dosage form of ceftriaxone sodium using enteric coated sustained release calcium alginate beads by Darshan Lalwani Submitted to the Graduate Faculty as partial fulfillment of the requirements for the Master of Science Degree in Pharmaceutical Sciences with Industrial Pharmacy option The University of Toledo May 2015 Purpose: Ceftriaxone (CTZ) is a broad spectrum semisynthetic, third generation cephalosporin antibiotic. It is an acid labile drug belonging to class III of biopharmaceutical classification system (BCS). It can be solvated quickly but suffers from the drawback of poor oral bioavailability owing to its limited permeability through
    [Show full text]
  • In Vitro Activity of Ceftibuten in Combination with VNRX-7145 And
    IHMA, Inc. In Vitro Activity of Ceftibuten in Combination with VNRX-7145 and Comparators 2122 Palmer Drive SUNDAY - AAR-721 Schaumburg, IL 60173 USA against 1,066 UTI Isolates Non-susceptible to Amoxicillin-clavulanate and Levofloxacin www.ihma.com M. Hackel1, D. Sahm1 1IHMA, Inc., Schaumburg, IL, USA INTRODUCTION RESULTS RESULTS SUMMARY VenatoRx is currently developing Table 1. In Vitro Activity of Ceftibuten/VNRX-5236 Against Enterobacteriaceae Isolates from Urinary Tract Infections Figure 2. Ceftibuten and Ceftibuten/VNRX-5236 MIC Distributions Figure 4. Ceftibuten and Ceftibuten/VNRX-5236 MIC Distributions . The MIC90 value for ceftibuten/VNRX-5236 VNRX-7145, a novel oral beta- Against 1,066 Enterobacteriaceae Non-susceptible to Amoxicillin- Against 61 KPC-producing Enterobacteriaceae Non-susceptible was 2 μg/mL, compared to >32 μg/mL for lactamase inhibitor in combination Organism, phenotype (n) Compound %S %I %R µg/mL clavulanate and Levofloxacin to Amoxicillin-clavulanate and Levofloxacin ceftibuten alone against all Enterobacteriaceae MIC MIC Range with ceftibuten to treat gram- 50 90 1000 40 (Table 1, Figure 2). negative infections resistant to front- Enterobacteriaceae (1066) Ceftibuten/VNRX-5236* 94.5 1.0 4.5 ≤0.25 2 ≤0.25 - > 32 Ceftibuten/VNRX-5236 Ceftibuten Ceftibuten/VNRX-5236 Ceftibuten . 94.5% of isolates were inhibited by Ceftibuten 58.3 13.0 28.8 8 > 32 0.12 - > 32 900 line oral agents. VNRX-7145 35 ceftibuten/VNRX-5236 at ≤8 μg/mL, and Amoxicillin-clavulanate 0.0 46.1 53.9 32 > 64 16 - > 64 undergoes biotransformation in vivo 89.1% were inhibited at 1 µg/mL compared to Ceftazidime-avibactam 97.2 0.0 2.8 0.25 2 ≤0.03 - > 32 800 to the active beta-lactamase in- Ceftolozane-tazobactam 55.9 8.3 35.8 2 > 8 ≤0.25 - > 8 30 58.3% susceptible to ceftibuten alone.
    [Show full text]
  • The New Fifth-Generation Cephalosporins – a Balance Between Safety and Efficacy
    REVIEWS Ref: Ro J Pharm Pract. 2020;13(3) DOI: 10.37897/RJPhP.2020.3.2 The new fifth-generation cephalosporins – a balance between safety and efficacy Aura Rusu1, Ioana-Andreea Lungu2 1 Pharmaceutical and Therapeutical Chemistry Department, Faculty of Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania 2 Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science and Technology, Targu Mures, Romania Abstract Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representa- tives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobi- prole medocaril. These new cephalosporins are valuable anti-infective agents, with potent activity against multidrug-re- sistant bacteria, and with a positive balance between benefits and side effects. However, the fifth-generation cephalosporins should be judiciously used to prevent the occurrence of bacterial resistance phenomenon. Keywords: cephalosporins, ceftaroline, ceftolozane, ceftobiprole, MRSA, community-acquired pneumonia, complicated skin and soft tissue infections INTRODUCTION emerged as a result of increased only, in the situation where other Cephalosporins (CFs) are beta- bacterial resistance to classical antibacterial drugs were not lactam antibiotics with numerous antibiotics. Based on the efficient. representatives widely used in the antimicrobial activity, the CFs are therapy
    [Show full text]
  • Citrobacter Koseri
    | Table 1 Antimicrobial activity of ceftibuten-clavulanate tested against the most common ASM Microbe 2019 Poster Sunday-AAR-718 Figure 1. Isolate Enterobacterales species stratified by geographic region MIC /MIC (% inhibited at ≤4 mg/L of ceftibuten-clavulanate) distribution by 50 90 Latin Organism (no. tested) USA EUR APAC LATAM All Antimicrobial Activity of Ceftibuten-Clavulanate When geographic region Enterobacterales 0.12/2 (93.3) 0.25/4 (90.4) 0.25/8 (89.2) 0.25/8 (88.3) 0.25/4 (91.0) America (5,568) E. coli (2,000) 0.25/1 (95.7) 0.25/1 (96.6) 0.25/1 (93.4) 0.25/1 (94.6) 0.25/1 (95.4) 13.8% K. pneumoniae 0.06/0.25 (97.7) 0.12/8 (87.7) 0.06/16 (87.4) 0.12/32 (82.9) 0.06/4 (90.5) Tested against Clinical Enterobacterales Isolates (1,850) K. oxytoca (346) ≤0.03/0.12 (100.0) ≤0.03/0.12 (99.3) ≤0.03/0.12 (96.7) ≤0.03/1 (100.0) ≤0.03/0.12 (99.4) United States Indole-positive 0.06/8 (88.4) 0.06/8 (89.7) 0.12/8 (84.0) 0.25/32 (76.0) 0.06/8 (87.6) Proteeae (331)a Collected Worldwide in 2017 Asia-Pacific 36.2% C. freudii (228) 2/64 (78.4) 2/64 (68.6) 4/64 (50.0) 2/64 (71.4) 2/64 (73.2) 15.2% P. mirabilis (210) ≤0.03/0.06 (96.0) ≤0.03/0.06 (93.3) ≤0.03/≤0.03 ≤0.03/≤0.03 (93.3) ≤0.03/0.06 (95.2) (100.0) Helio S.
    [Show full text]
  • Guidelines on Urological Infections
    Guidelines on Urological Infections M. Grabe (Chairman), T.E. Bjerklund-Johansen, H. Botto, M. Çek, K.G. Naber, P. Tenke, F. Wagenlehner © European Association of Urology 2010 TABLE OF CONTENTS PAGE 1. INTRODUCTION 7 1.1 Pathogenesis of urinary tract infections 7 1.2 Microbiological and other laboratory findings 7 1.3 Classification of urological infections 8 1.4 Aim of guidelines 8 1.5 Methods 9 1.6 Level of evidence and grade of guideline recommendations 9 1.7 References 9 2. UNCOMPLICATED URINARY TRACT INFECTIONS IN ADULTS 11 2.1 Definition 11 2.1.1 Aetiological spectrum 11 2.2 Acute uncomplicated cystitis in premenopausal, non-pregnant women 11 2.2.1 Diagnosis 11 2.2.1.1 Clinical diagnosis 11 2.2.1.2 Laboratory diagnosis 11 2.2.2 Therapy 11 2.2.3 Follow up 12 2.3 Acute uncomplicated pyelonephritis in premenopausal, non-pregnant women 12 2.3.1 Diagnosis 12 2.3.1.1 Clinical diagnosis 12 2.3.1.2 Laboratory diagnosis 12 2.3.1.3 Imaging diagnosis 13 2.3.2 Therapy 13 2.3.2.1 Mild and moderate cases of acute uncomplicated pyelonephritis 13 2.3.2.2 Severe cases of acute uncomplicated pyelonephritis 13 2.3.3 Follow-up 14 2.4 Recurrent (uncomplicated) UTIs in women 16 2.4.1 Diagnosis 16 2.4.2 Prevention 16 2.4.2.1 Antimicrobial prophylaxis 16 2.4.2.2 Immunoactive prophylaxis 16 2.4.2.3 Prophylaxis with probiotics 17 2.4.2.4 Prophylaxis with cranberry 17 2.5 Urinary tract infections in pregnancy 17 2.5.1 Definition of significant bacteriuria 17 2.5.2 Screening 17 2.5.3 Treatment of asymptomatic bacteriuria 17 2.5.4 Duration of therapy 18 2.5.5 Follow-up 18 2.5.6 Prophylaxis 18 2.5.7 Treatment of pyelonephritis 18 2.5.8 Complicated UTI 18 2.6 UTIs in postmenopausal women 18 2.6.1 Risk factors 18 2.6.2 Diagnosis 18 2.6.3 Treatment 18 2.7 Acute uncomplicated UTIs in young men 19 2.7.1 Men with acute uncomplicated UTI 19 2.7.2 Men with UTI and concomitant prostate infection 19 2.8 Asymptomatic bacteriuria 19 2.8.1 Diagnosis 19 2.8.2 Screening 19 2.9 References 26 3.
    [Show full text]
  • Virulence and Resistance in Staphylococcus Aureus: 2016 State of the Art Lyon, France
    Antimicrobial susceptibility tests for Staphylococcus aureus and EUCAST recommendations Virulence and Resistance in Staphylococcus aureus: 2016 State of the Art Lyon, France. 28 June – 1 July, 2016 © by author Dr. Rafael Cantón ESCMIDHospital Universitario Online Ramón y Cajal Lecture Library SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad Complutense. Madrid Antimicrobial susceptibility testing (AST) CLSI (NCCLS) EUCAST CLINICAL BREAKPOINTS CLINICAL BREAKPOINTS EPIDEMIOLOGYCAL CUT-OFF © by author ESCMID Online Lecture Library © by author www.eucast.org ESCMID Online Lecture Library MIC testing versus detection of resistance Susceptibility MIC Mechanism of resistance Mechanism© by author of resistance ESCMID Online Lecture Library Susceptibility MIC Clinical breakpoints: the philosophy . The aim of clinical breakpoints is to use MIC values … - to separate strains where there is a high likelihood of treatment success from those where treatment is more likely to fail - to adequately treat patients but not to detect resistance mechanisms from a microbiological point of view . Clinical breakpoints have not been created to detect resistance mechanisms . They are ultimately derived© by from author human clinical studies comparing outcomes with the MICs for the infecting pathogen . If clinical breakpoints are well established no actions (expert ESCMID rules) are needed Online beyond MIC Lecture interpretation Library (interpretive reading) .. but this has not been the case in the past! Interpretive reading of AST results . During more than twenty years interpretive reading of the antibiogram has been used to: - infer resistance mechanisms behind resistant phenotypes - identify resistant organisms for infection control purposes - apply expert rules* and modify (when needed!) previous clinical categorization Courvalin P. ASM News 19921992;58:368-75 Livermore et al.
    [Show full text]
  • Association of Cardiovascular Risk with Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: a Nested Case-Control Study
    Supplementary Online Content Wang M-T, Liou J-T, Lin CW, et al. Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. JAMA Intern Med. Published online January 2, 2018. doi: 10.1001/jamainternmed.2017.7720 eMethods 1. Development of a disease risk score-matched nested case-control study eMethods 2. Modeling a nonlinear duration-response association using a restricted cubic splines function model. eMethods 3. A case-crossover study for assessing the association between the CVD risk and use of LABAs and LAMAs eTable 1. Diagnosis codes used to define the comorbidities and individual drugs of comedications eTable 2. Comparison of CVD risk between new LAMA use and new LABA use eTable 3. Risk of each primary cardiovascular outcome with new LABA and LAMA use eTable 4. Case-crossover analysis for the risk of CVDs with use of LABA and LAMA within 30 days eTable 5. Clinical characteristics of CVD patients during the case and control periods in an alternative case-crossover study eTable 6. Numbers needed to harm for patients who had an increased CVD risk from using LABAs and LAMAs in our primary and secondary analyses eFigure 1. Overview for the adopted nested case-control study design. CVD, cardiovascular disease; COPD, chronic obstructive pulmonary disease; ER, emergency room; NHI represents National Health Insurance eFigure 2. Specification of case and control periods in an alternative case-crossover study eFigure 3. The impact of unmeasured confounders assessed by the rule-out method eFigure 4. Study flow diagram outlining the selection of study cohort © 2018 American Medical Association.
    [Show full text]